Therapeutic Potential of Biogenic Silver Nanoparticles in Murine Cutaneous Leishmaniasis

Abstract:

Many efforts in these last years have dedicated in the development of new drugs due to an increase of microbial organisms resistant to multiple antibiotics, and silver nanoparticles appears as a novel antimicrobial agent. The aim of our work was to evaluate the in vitro and in vivo antileishmanial activity of the silver nanoparticles prepared by chemical process and by biosynthesis from Fusarium oxysporum. In vitro antipromastigote activity of L. amazonensis showed that silver nanoparticles chemically synthesized (AgCHEM), biogenic silver nanoparticles (AgBIO) and amphotericin B decreased the parasite load up to 13%, 61%, and 68%, respectively. The IC₅₀ of AgCHEM and AgBIO was 103.5 ± 11.5 μM and 31.6 ± 8.2 μM respectively. The assay of antileishmanial effect of these nanoparticles was evaluated in vivo (BALB/c mice) against L. amazonensis. The mice infected with promastigotes of L. amazonensis in the ear showed that after 10 days of treatment (twice a week for four weeks) the wound in the control (mice treated with PBS solution) was large, while the wound of the mice treated with amphotericin B (positive control) exhibited low size of lesion. The same parasitemia inhibition with amphotericin B was observed when AgBIO were used at 300 fold lower concentration, and 100 fold less concentration of AgCHEM than amphotericin B. Thus, these nanoparticles can be used in wound helping like cutaneous leishmaniasis.

• Periodical: Journal of Nano Research (Volume 20)
• Pages: 89-97
• DOI: https://doi.org/10.4028/www.scientific.net/JNanoR.20.89
• Online since: December 2012
• Authors: Bartira Rossi-Bergmann, Wallace Pacienza-Lima, Priscyla D. Marcato, Roseli de Conti, Nelson Durán
• Keywords: Biogenic, In Vivo, Leishmaniasis, Silver Nanoparticle

References

[1] J. Alvar, I.D. Vélez, C. Bern, M. Herrero, P. Desjeux, J. Cano, J. Jannin, M. Boer, The WHO Leishmaniasis Control Team, Leishmaniasis. Worldwide and global estimates of its incidence, Plos One. 7 (2012) e35671.

DOI: 10.1371/journal.pone.0035671

[2] T. Garnier, S.L. Croft, Topical treatment for cutaneous leishmaniasis, Curr Opin Investig Drugs. 3 (2002) 538-544.

[3] A.M. Alkhawajah, E. Larbi, Y. al-Gindan, A. Abahussein, S. Jain, Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration, Ann Trop Med Parasitol. 91 (1997) 899-905.

DOI: 10.1080/00034983.1997.11813217

[4] I. Esfandiarpour, S. Farajzadeh, Z. Rahnama, E. A. Fathabadi, A. Heshmatkhah, Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis, International Journal of Dermatology. 10 (2012).

DOI: 10.1111/j.1365-4632.2012.05460.x

[5] M. Navarro, E. J. Cisneros-Fajardo and E. Marchan, New silver polypyridyl complexes: synthesis, characterization, and biological activity on Leishmania Mexicana, Arzn. Forsch. 56 (2006) 600-604.

DOI: 10.1055/s-0031-1296758

[6] A.B. Seabra, and N. Durán, Nitric oxide-releasing vehicles for biomedical applications, Journal of Materials Chemistry. 20 (2010) 1624-1637.

DOI: 10.1039/b912493b

[7] E.C. Torres-Santos, M.I. Sampaio-Santos, F.S. Buckner, K. Yokoyama, M. Gelb, J. A. Urbina, B. Rossi-Bergmann, Altered sterol profile induced in Leishmania amazonensis by a natural dihydroxymethoxylated chalcone, J. Antimicrob. Chemother. 63 (2009).

DOI: 10.1093/jac/dkn546

[8] I. Arevalo, B. Ward, R. Miller, T.C. Meng, E. Najar, E. Alvarez, G. Matlashewski, A. Llanos-Cuentas, Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator, Clinical Infectious Diseases. 33 (2001).

DOI: 10.1086/324161

[9] A.M. Allahverdiyev, S.A. Emrah, M. Bagirova, C.B. Ustundag, C. Kaya, F. Kaya, and M. Rafailovich, Antileishmanial effect of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet light, Int J Nanomedicine. 6 (2011).

DOI: 10.2147/ijn.s23883

[10] P.D. Marcato, R. De Conti, B. Rossi-Bergmann and N. Durán, Silver nanoparticles/clindamycin: antileishmanial activity VII Ann. Meeting of SBPMat, (2008) September 28-October 2, Guarujá-SP, Brasil.

[11] P. Mohanpuria, P.N.K. Rana, and S.K. Yadav, Biosynthesis of nanoparticles: technological concepts and future applications J. Nanopart. Res. 10 (2008) 507-517.

DOI: 10.1007/s11051-007-9275-x

[12] V.K. Sharma, R.A. Yngard, and Y. Lin, Silver nanoparticles: Green synthesis and their antimicrobial activities Advan. Colloid Interf. Sci. 145 (2009) 83-96.

DOI: 10.1016/j.cis.2008.09.002

[13] V. Deepak, P.S. Umamaheshwaran, K. Guhan, R.A. Nanthini, B. Krithiga, N.M.H. Jaithoon, S. Gurunathan, Synthesis of gold and silver nanoparticles using purified. Collids and Surfaces B-Biointerfaces, 86 (2011) 353-358.

DOI: 10.1016/j.colsurfb.2011.04.019

[14] N. Durán, P.D. Marcato, M. Durán, A. Yadav, A. Gade, M. Rai, Mechanistic aspects in the biogenic synthesis of extracellular metal nanoparticles by peptides, bacteria, fungi, and plants. Applied Microbiology and Biotechnology. 90 (2011) 1609-1624.

DOI: 10.1007/s00253-011-3249-8

[15] G.P. Pei, L.S.F.Y. Yau, Potential of plant as a biological factory to synthesize gold and silver nanoparticles and their applications, Reviws in Environmental Science and Bio-technology. 11 (2012) 169-206.

DOI: 10.1007/s11157-012-9278-7

[16] T.N.V.K.V. Prasad, V.S.R. Kambala, R. Naidu, A Critical Review on Biogenic Silver Nanoparticles and their Antimicrobial Activity. Current Nanoscience. 4 (2011) 531-544.

DOI: 10.2174/157341311796196736

[17] N. Durán, P.D. Marcato, O.L. Alves, H.I.H. De Souza, and E. Esposito, Mechanistic aspects of biosyntheis of silver nanoparticles by several Fusarium oxysporum strains. J. Nanobiotechnol. 3 (2005) 1-7.

DOI: 10.1186/1477-3155-3-8

[18] N. Durán, P.D. Marcato, H.I.H. De Souza, O.L. Alves, and E. Esposito, Antibacterial effect of silver nanoparticles produced by fungal process on textile fabrics and their effluent treatment. J. Biomed. Nanotechnol. 3 (2007) 203-208.

DOI: 10.1166/jbn.2007.022

[19] M. Mohebali, M.M. Rezayat, K. Gilani, S. Sarkar, B. Akhoundi, J. Esmaeili, T. Satvat, S. Elikaee, S. Charehdar, H. Hooshyar, Nanosilver in the treatment of localized cutaneous leishmaniasis caused by Leishmania major (MRHO/IR/75/ER): an in vitro and in vivo study. DARU. 17 (2009).

DOI: 10.1007/s00436-019-06382-y

[20] A.M. Allahverdiyev, E.S. Abamor, M. Bagirova, C.B. Ustundag, C. Kaya, F. Kaya, M. Rafailovich, Antileishmanial effect of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet light. International Journal of Nanomedicine. 6 (2011).

DOI: 10.2147/ijn.s23883

[21] B. Rossi-Bergmann, C.A.B. Falcão, A. Lenglet, C.R. Bezerra-Santos, D. Costa-Pinto and Y.M. Traub-Czeko, A simple fluorimetric method for assessing drug and vaccine efficacy in cutaneous leishmaniasis using Leishmania amazonensis expressing green fluorescence protenin Mem. I. Oswaldo Cruz (Suppl. II), 94 (1999).

[22] F.C. Silva Filho, E.M. Saraiva, M.A. Santos, W. de Souza, The surface free energy of Leishmania mexicana amazonensis. Cell Biophys. 2 (1990) 137-51.

[23] S.L. Croft, and G.H. Coombs, Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends in Parasitology. 19 (2003) 502-508.

DOI: 10.1016/j.pt.2003.09.008

[24] F.J. Abajo and A.J. Carcas Amphotericin-B Hepatotoxicity. British Medical Jounal. 293 (1986) 1243-1243.

DOI: 10.1136/bmj.293.6556.1243-b

[25] I. Karimzadeh, S. Farsaei, H. Khalili, S. Dashti-Khavidaki, Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity? Expert Opinion on Drug Safety. 11 (2012) 969-983.

DOI: 10.1517/14740338.2012.721775